98%
921
2 minutes
20
Cisplatin is a widely used chemotherapeutic agent for treating solid tumors. However, its extensive clinical application raises environmental concerns, as it has been detected in wastewater effluents at concentrations as high as 150 μg/L. Even though recent studies indicate that even sub-lethal concentrations of cisplatin may induce neurobehavioral toxicity in aquatic organisms, the precise mechanism underlying cisplatin-induced behavioral disturbances remains unclear. Considering the above and that the neurotoxic impact of cisplatin on aquatic vertebrates remains unexplored mainly, this study sought to address two key objectives: 1) to determine whether cisplatin induces neurotoxic effects in fish and 2) to investigate the mechanisms through which cisplatin may cause neurobehavioral changes in these organisms. The findings revealed that zebrafish exposed to cisplatin concentrations of 2, 5, and 10 μg/L experienced a marked reduction in locomotor activity, with pronounced periods of immobility and the emergence of anxiety-like behaviors. Furthermore, exposure to cisplatin over 96 h led to considerable disruptions in redox balance and acetylcholinesterase (AChE) activity, characterized by a pronounced enzymatic inhibition. Likewise, gene expression analyses further demonstrated that cisplatin exposure upregulated pathways associated with apoptosis and mitochondrial dysfunction while concurrently downregulated pathways linked to neuronal protection and muscle development. Overall, these findings underscore cisplatin's broad and multifaceted effects on zebrafish, involving both behavioral and biochemical alterations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.scitotenv.2025.179776 | DOI Listing |
Int J Clin Oncol
September 2025
Department of Urology, University of Tsukuba Institute of Medicine, Tsukuba, Ibaraki, 305-8575, Japan.
Metastatic urothelial carcinoma (mUC) remains a disease with poor prognosis. While conventional platinum-based chemotherapy has long served as the standard first-line treatment, its survival benefit is limited, particularly in cisplatin-ineligible patients. The introduction of immune checkpoint inhibitors and antibody-drug conjugates as part of sequential treatment has improved outcomes, with pembrolizumab, avelumab, and enfortumab vedotin (EV) providing survival benefit in later lines.
View Article and Find Full Text PDFUrologie
September 2025
Klinik für Urologie, Medizinisches Forschungszentrum, Urologisches Forschungslabor, Translationale UroOnkologie, Medizinische Fakultät und Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland.
Type II testicular germ cell tumors (GCT) are the most common malignant disease in young men, with a steadily increasing incidence. They originate from germ cell neoplasia in situ and are classified into seminomas (SE) and nonseminomas (NS). The NS subtype embryonal carcinoma (EC) exhibits stem cell-like characteristics and, thus, has the potential to differentiate into teratomas (TE) or extraembryonic tissues, such as yolk-sac tumors (YST) and choriocarcinomas (CC).
View Article and Find Full Text PDFCancer Med
September 2025
Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Background: Esophageal squamous cell carcinoma (ESCC) represents an aggressive cancer type associated with poor prognosis, often treated with neoadjuvant chemotherapy (NAC) using cisplatin-based regimens. However, cisplatin resistance limits therapeutic efficacy, necessitating a deeper understanding of resistance mechanisms. L-type amino acid transporter 1 (LAT1) plays a crucial role in amino acid uptake and is linked to cancer cell survival through activation of the mammalian target of rapamycin (mTOR) pathway.
View Article and Find Full Text PDFCancer Rep (Hoboken)
September 2025
Department of Pediatric Surgery, Nihon University School of Medicine, Tokyo, Japan.
Background: Alpha-fetoprotein (AFP)-producing gastric cancer (AFPGC) is resistant to chemotherapy and is associated with poor prognosis. Pediatric gastric cancer has an incidence of 0.02% among gastric cancer patients, with a median survival of 5 months.
View Article and Find Full Text PDFJ Biophotonics
September 2025
Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, USA.
Ovarian cancer (OvCa) remains the leading cause of gynecological cancer mortality, with most patients developing chemoresistance. Drug repurposing offers promising alternatives, with mebendazole (MBZ) showing anticancer activity. This study evaluates MBZ efficacy using Spectral Domain Optical Coherence Tomography (SD-OCT).
View Article and Find Full Text PDF